Dynavax Technologies
2100 Powell Street
Suite 300
Emeryville
California
94608
United States
Tel: 510-848-5100
Fax: 510-848-1379
Website: http://www.dynavax.com/
Email: contact@dynavax.com
About Dynavax Technologies
We are developing immunotherapies based on cutting-edge Toll-like receptor (TLR) biology and its ability to modulate the immune system.
463 articles about Dynavax Technologies
-
Elaine D. Sun Appointed to Dynavax Board of Directors - Dec 14, 2021
12/14/2021
Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines to protect the world against infectious diseases, announced the appointment of Elaine Sun to its Board of Directors.
-
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 02, 2021
12/2/2021
Dynavax Technologies Corporation reported that it has granted nonstatutory stock options to purchase an aggregate of 58,500 shares of Dynavax common stock as inducements to 5 newly-hired employees in connection with commencement of employment with the Company.
-
Dynavax Reports Third Quarter 2021 Financial Results
11/4/2021
Dynavax Technologies Corporation today reported financial results for the third quarter ended September 30, 2021 and provided a business update.
-
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 02, 2021
11/2/2021
Dynavax Technologies Corporation reported that it has granted nonstatutory stock options to purchase an aggregate of 5,000 shares of Dynavax common stock as inducements to 1 newly-hired employee in connection with commencement of employment with the Company.
-
Scott Myers Appointed to Dynavax Board of Directors and Elected Board Chairman
10/21/2021
Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, announced the appointment of Scott Myers to its Board of Directors.
-
Dynavax to Report Third Quarter 2021 Financial Results and Host Conference Call on November 4, 2021
10/21/2021
Dynavax Technologies Corporation will report third quarter 2021 financial results on Thursday, November 4, 2021, after the U.S. financial markets close.
-
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 18, 2021
10/18/2021
Dynavax Technologies Corporation reported that it has granted nonstatutory stock options to purchase an aggregate of 115,000 shares of Dynavax common stock as inducements to 1 newly-hired employee in connection with commencement of employment with the Company.
-
COVID-19 Vaccine Developed by Valneva Using Dynavax's CpG 1018 Adjuvant Meets Both Co-Primary Endpoints in Phase 3 COV-COMPARE Trial
10/18/2021
Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing vaccines, announced that Valneva SE reported positive topline results from the Phase 3 pivotal trial of VLA2001, their inactivated COVID-19 vaccine candidate using Dynavax's CpG 1018® adjuvant.
-
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2021
10/1/2021
Dynavax Technologies Corporation reported that it has granted nonstatutory stock options to purchase an aggregate of 40,000 shares of Dynavax common stock as inducements to 1 newly-hired employee in connection with commencement of employment with the Company.
-
Dynavax to Present at Upcoming Investment Conferences
9/27/2021
Dynavax Technologies Corporation today announced that it will participate in the following investor conferences. 2021 Cantor Virtual Global Healthcare Conference Dynavax Presentation: Thursday, September 30, 2021, 12:00 p.m. E.T.
-
COVID-19 Vaccine Developed by Clover Biopharmaceuticals Using Dynavax's CpG 1018 Adjuvant Meets Primary and Secondary Efficacy Endpoints in Global Phase 2/3 Trial
9/22/2021
Dynavax Technologies Corporation today announced that Clover Biopharmaceuticals (Clover) reported positive data for their protein-based COVID-19 vaccine candidate, SCB-2019
-
Dynavax Provides Update on its COVID-19 Collaboration with Valneva
9/13/2021
Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing vaccines, announced that Valneva SE has received a termination notice from the United Kingdom Government in relation to Valneva's supply agreement for its COVID-19 vaccine candidate, VLA2001.
-
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 02, 2021
9/2/2021
Dynavax Technologies Corporation reported that it has granted nonstatutory stock options to purchase an aggregate of 224,000 shares of Dynavax common stock as inducements to 8 newly-hired employees in connection with commencement of employment with the Company.
-
Dynavax Announces Second Quarter 2021 Financial Results
8/4/2021
Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, reported financial results for the second quarter of 2021.
-
Dynavax and Biological E Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Biological E's COVID-19 Vaccine Candidate
7/6/2021
Biological E to purchase CpG 1018 adjuvant from Dynavax for use in the commercial production of Biological E's COVID-19 vaccine candidate, CORBEVAX™
-
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 02, 2021
7/2/2021
Dynavax Technologies Corporation reported that it has granted nonstatutory stock options to purchase an aggregate of 51,000 shares of Dynavax common stock as inducements to 5 newly-hired employees in connection with commencement of employment with the Company.
-
Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate - June 30, 2021
6/30/2021
Clover Biopharmaceuticals and Dynavax Technologies Corporation announced the execution of a commercial supply agreement of Dynavax's CpG 1018™ advanced adjuvant, for use in Clover's protein-based COVID-19 vaccine candidate, SCB-2019.
-
Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate
6/30/2021
Clover Biopharmaceuticals and Dynavax Technologies Corporation announced the execution of a commercial supply agreement of Dynavax's CpG 1018TM advanced adjuvant, for use in Clover's protein-based COVID-19 vaccine candidate, SCB-2019.
-
Dynavax Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 29, 2021
6/29/2021
Dynavax Technologies Corporation announced that, in connection with the appointment of John Slebir as Senior Vice President, General Counsel on June 28, 2021, the Company granted him a non-statutory stock option to purchase 300,000 shares of Dynavax common stock.
-
Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany
5/27/2021
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B [Hepatitis B Vaccine (Recombinant), Adjuvanted] in Germany